BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data

BioNTech SE (NASDAQ:BNTX) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts.

BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data

BioNTech SE (NASDAQ:BNTX) is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases.

On April 13, BofA raised its price target on BioNTech SE (NASDAQ:BNTX) from $128 to $130, while maintaining a ‘Buy’ rating on the shares. The revised target indicates an upside of almost 20% from the current price levels.

The move comes after BioNTech SE (NASDAQ:BNTX) reported positive Phase 2 results for T-Pam in second-line and later HER2-expressing endometrial cancer. The analyst firm found these results encouraging and noted that they support a potential first approval within BioNTech’s expanding oncology pipeline.

BioNTech SE (NASDAQ:BNTX) is targeting total revenues in the range of €2 billion to €2.3 billion for FY 2026, down from €2.9 billion in 2025. The company expects lower revenue from the COVID-19 vaccine it developed in partnership with Pfizer, driven by declines in both the European and United States markets. Moreover, the YoY decline comes from a lack of expected one-time revenues, such as payments from Pfizer’s opt-out of the shingles program last year.

While we acknowledge the risk and potential of BNTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BNTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 8 Best Wind Power and Solar Stocks to Buy Right Now and 10 Best Affordable Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.